Clinical Trial Update: A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating tislelizumab combined with TACE and lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• TACE
• Tislelizumab (tislelizumab)

Snippet

Sponsor: First Affiliated Hospital of Fujian Medical University | Conditions: Hepatocellular Carcinoma Resectable | Phase 4 | Status: UNKNOWN